Hologic has announced FDA clearance for its Genius Digital Diagnostics System, marking it as the first digital cytology system approved by the FDA that utilizes artificial intelligence (AI) and advanced imaging to enhance cervical cancer screening according to the company. The solution aims to improve the accuracy of detecting pre-cancerous lesions and cervical cancer cells, streamline workflow in laboratories, and elevate patient…
Matrix Health and Care has been granted a patent from the USPTO for Matrix, an innovative self-use pelvic assessment tool aimed at enhancing gynecological examinations. Distinct from traditional speculums, Matrix emphasizes patient comfort and control, allowing for self-administration in clinical settings and integrating real-time data transmission for clinical evaluation and research. The patent marks a significant milestone for Matrix Health & Care…
Teal Health is making strides in cervical cancer prevention with the SELF-CERV clinical study of its Teal Wand, an at-home self-collect device for cervical cancer screening. The study, underway at top health institutions such as Johns Hopkins, Yale University, and the University of Colorado, supports FDA submission and approval of the device. Teal Health’s initiative aims to provide a convenient and less…
Landing Med, a Chinese medtech company focused on early cancer detection, has achieved a significant milestone by completing over 10 million cervical cancer screenings using artificial intelligence (AI). Established by Dr. Xiaorong Sun, the company has been integrating automation, digital, AI, and cloud computing technologies into Pap smear testing across China since 2017. “I started Landing Med to address the challenge of…
Asieris Pharmaceuticals has launched a new Women’s Health Business Unit, focusing on advancing treatments in gynecology, particularly for cervical cancer. The initiative centers on APL-1702, a non-surgical treatment for cervical high-grade squamous intraepithelial lesions, positioning the company at the forefront of innovative gynecological care. This move aligns with global health initiatives aimed at combating cervical cancer. The China National Program for Women’s…
Pearsanta, a subsidiary of Aditxt, has recently acquired the Mitomic testing platform from MDNA Life Sciences. The transaction, valued at approximately $25 million, is a strategic expansion for Pearsanta, enhancing its capabilities in early disease and cancer detection, particularly in women’s health, focusing on conditions such as endometriosis and ovarian cancer. The Mitomic technology utilizes mitochondrial DNA (mtDNA) to detect diseases at…
GE HealthCare has announced the release of MyBreastAI Suite, a new AI-powered platform for mammography, designed to aid clinicians in detecting breast cancer. This platform integrates AI applications from iCAD, focusing on breast density assessment and enhancing the efficiency of mammography workflows. Addressing the challenges posed by the global rise in breast cancer cases, MyBreastAI Suite aims to streamline breast cancer detection.…
MiMARK Diagnostics, a company specializing in women’s health, has completed its first seed funding round, raising €4.22M. The funds are intended to advance their work in gynecological diagnostics, focusing on the use of gynecological fluids as a non-invasive source for biomarker detection. The company received €1.5M from EIT Health back in 2021. MiMARK is developing in vitro diagnostic solutions for managing gynecological…
